Looking out for latest news on Pharma Magazine?
Check out the latest Pharma news, Top news in Pharma Magazine, Leading Magazine in Pharma industry. Daily news updates pertinent to the industrial sectors we are engaged with are depicted on the news section of Pharma industry which we operate.
Vertex Pharmaceuticals Incorporated has unveiled significant progress in its suzetrigine pain program potentially marking a breakthrough in acute and neuropathic pain treatment Suzetrigine an oral selective
PharmaTher Holdings Ltd a specialized pharmaceutical firm has received a Complete Response Letter regarding its Priority Original Abbreviated New Drug Application
TaiGen Biotechnology Company Limited has announced today that its business partner Joincare Pharmaceutical has concluded the unblinding process for the phase III study of the influenza antiviral TG Initial findings indicate that TG significantly redu...
Evaxion Biotech AS a clinicalstage TechBio company specializing in AIImmunology powered vaccines has achieved a significant milestone in its EVX Phase trial for metastatic melanoma
ABVC BioPharma Inc has unveiled a significant licensing deal with OncoX a company specializing in oncology dietary supplements with the goal of advancing treatments for NonSmall Cell Lung Cancer
SCG Cell Therapy and the Agency for Science Technology and Research have announced the inauguration
Precision BioSciences Inc a leading gene editing company has declared the anticipated return of three programs previously under Prevail Therapeutics Inc a subsidiary of Eli Lilly and Company
Enlivex Therapeutics Ltd has received authorization from the Danish Medicines Agency to expand its Phase III trial for Allocetra into Denmark This development follows the initial approval
Reviva Pharmaceuticals Holdings Inc a prominent latestage pharmaceutical company specializing in addressing unmet medical needs in central nervous system inflammatory
Imugene Limited has initiated enrollment for its expansion study targeting bile tract cancer patients This comes after completing the fifth cohort in the high dose segment of the intratumoural
